Share price · ONCY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ONCY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+15.1%
Nothing announced by ONCY that day or the session before.
- 17 Nov 2026+12.5%
Nothing announced by ONCY that day or the session before.
- 9 Nov 2026-7.2%
- 14 Oct 2026+9.8%
- 12 Oct 2026-15.0%
- 8 Oct 2026-8.6%
Nothing announced by ONCY that day or the session before.
- 5 Oct 2026-5.4%
Nothing announced by ONCY that day or the session before.
- 22 Sep 2026-6.9%
Nothing announced by ONCY that day or the session before.
- 14 Sep 2026+9.0%
Nothing announced by ONCY that day or the session before.
- 9 Jul 2026+16.1%
- Day beforeChange of certifying accountant
Share of unusual movement by asset
For each asset, the share of ONCY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Tumor cells (oncolytic replication)Oncolytic virus | Colorectal Cancer Advanced Metastatic Colorectal Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
July 2027 (1)
What to watch
August 2027 (1)
What to watch
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $5.2M | $2.4M | $9.7M-$6.9M operating cash flow | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $4.3M | $4.1M | $9.4M-$8.1M operating cash flow | report ↗ |
| 2026-Q1 | — | $4.5M | $5.5M | $9.2M-$7.3M operating cash flow | report ↗ |
| 2025-Q3 | — | $5.1M | $8.9M | $9.9M-$4.8M operating cash flow | report ↗ |
| 2025-Q2 | — | $1.9M | $11M | $5.3M-$4.1M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.8M | $11M | $4.7M-$4.7M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $3.8M | —-$20M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 14 purchases ($363K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-01 | Glover Stephen C. · director | Award / grant (derivative) | 96,000 | — | — | Form 4 |
| 2026-06-01 | McAdory John Bearden · Chief Operating Officer | Award / grant (derivative) | 145,000 | — | — | Form 4 |
| 2026-06-01 | Heineman Thomas Charles · Chief Medical Officer | Award / grant (derivative) | 260,000 | — | — | Form 4 |
| 2026-06-01 | Brown Deborah Margaret · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-01 | Hagerman Allison · Chief Technology Officer | Award / grant (derivative) | 260,000 | — | — | Form 4 |
| 2026-06-01 | Seizinger Bernd R. · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-01 | Andrews Patricia S · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-01 | Kelly Jared · director, Chief Executive Officer | Award / grant (derivative) | 755,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2 reporting institutions held 0.9M shares ($731K, 0.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 859,831 | $731K |
| 2 | Sound Income Strategies, LLC | 194 | $180 |